Genetic Severity Score predicts clinical phenotype in NF2

Area of Science:

• Genetics
• Oncology
• Neurology

Background:

• Neurofibromatosis type 2 (NF2) exhibits variable clinical severity.
• Genetic mutations in NF2, such as truncating or missense variants, correlate with disease presentation.
• Understanding genotype-phenotype correlations is crucial for NF2 prognosis and management.

Purpose of the Study:

• To validate the UK NF2 Genetic Severity Score as a tool for assessing NF2 clinical phenotype.
• To correlate genetic severity with clinical manifestations in a cohort of NF2 patients.

Main Methods:

• Assessed the clinical phenotype of 142 NF2 patients.
• Utilized the UK NF2 Genetic Severity Score for correlation analysis.

Main Results:

• The score significantly correlated with 10 key clinical measures, including age at diagnosis, tumor presence (vestibular schwannomas, meningiomas), hearing status, and treatment timelines.
• Patients with severe NF2 presented earlier, had higher disease burden, and required more interventions.
• Significant correlations were observed with age at hearing loss, mortality, quality of life, and intervention frequency.

Conclusions:

• The UK NF2 Genetic Severity Score is validated for stratifying NF2 patients.
• This score is a valuable tool for both clinical practice and natural history research in NF2.